Jiangxi Sanxin Medtec (300453.SZ) subsidiary receives medical device registration certificate for mobile hemodialysis water treatment system.
Sanxin Medical (300453.SZ) issued an announcement that its controlling subsidiary, Chengdu Weili Sheng Biological Technology Co., Ltd. (...
Jiangxi Sanxin Medtec (300453.SZ) announced that its holding subsidiary Chengdu Weilisheng Biotechnology Co., Ltd. ("Chengdu Weilisheng") recently obtained a "Medical Device Registration Certificate" issued by the Sichuan Provincial Drug Administration for a mobile blood dialysis water production system.
The mobile blood dialysis water production system, for which Chengdu Weilisheng obtained the medical device registration certificate, consists of particle filters, activated carbon filters (cartridge filters), softeners (cartridge filters), reverse osmosis devices, transportation pipelines, disinfection systems (chemical disinfection devices), electrical control systems, and control software (release version V1). The acquisition of this medical device registration certificate further supplements the company's product chain in the field of blood purification medical equipment, improves the company's industrial layout, and will have a positive impact on the company's future production and operation.
Related Articles

CU VENTURE INV (08159) announced a net loss of HK$40.425 million for the middle of 2024, representing a 75.11% increase year-on-year.

NETDRAGON (00777) takes EDA strategy towards the international stage, AI + dual-wheel drive NETDRAGON aims for a market value of billions.

CU VENTURE INV (08159) announces a full-year net loss of HKD 4.268 million in 2024.
CU VENTURE INV (08159) announced a net loss of HK$40.425 million for the middle of 2024, representing a 75.11% increase year-on-year.

NETDRAGON (00777) takes EDA strategy towards the international stage, AI + dual-wheel drive NETDRAGON aims for a market value of billions.

CU VENTURE INV (08159) announces a full-year net loss of HKD 4.268 million in 2024.

RECOMMEND

Goldman Sachs Introduces China’s “Top Ten Giants” to Rival the U.S. “Magnificent Seven”
17/06/2025

Government Subsidies and Pricing Tactics Draw Scrutiny During 618 Festival: Midea Accused of Price Manipulation
17/06/2025

Profitability Remains Strong: Four Key Characteristics Behind Winning Hong Kong IPOs
17/06/2025